Why the study?
Although platelet function testing (PFT)-guided antiplatelet therapy is beneficial post-PCI, its efficacy in cerebral infarction remains controversial with considerable variability in clinical application.
Does platelet function testing (PFT)-guided antiplatelet therapy reduce ischemic and bleeding events in patients with cerebral infarction?
Design
Review
Key result
Platelet function testing-guided antiplatelet therapy offers potential to overcome drug resistance and guide de-escalation strategies in patients with cerebral infarction.
Authors
Loading...
CYP2C19-guided antiplatelet dosing may reduce ischemic events after stroke; leaves open prospective trials for bleeding risk and non-genetic factors.
Does platelet function testing (PFT)-guided antiplatelet therapy reduce ischemic and bleeding events in patients with cerebral infarction?
PFT-guided antiplatelet therapy offers a potential strategy to individualize treatment and reduce both ischemic and bleeding events in patients with cerebral infarction, though its current application remains variable.
Zhu et al. (2026) conducted a review in cerebral infarction. Platelet function testing (PFT)-guided antiplatelet therapy was evaluated. Platelet function testing-guided antiplatelet therapy offers potential to overcome drug resistance and guide de-escalation strategies in patients with cerebral infarction.